Onureg (Azacitidine) Patent Expiration, LOE Window & CMS Spending
Onureg (Azacitidine) by Bristol Myers Squibb: FDA Orange Book LOE 2030-06-03, 0 AB generics, $102.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N214120 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-06-03 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $102.7M |
| 2024 Medicare Part D Spend | $85.9M |
| 2024 Medicaid Spend | $16.8M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 20.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.